At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Postmarketing Study Of Lybrel In Relation To Venous Thromboembolism
In Brief
An observational study evaluating 90ug levonorgestrel / 20 ug ethinyl estradiol and Oral Contraceptives containing 20 ug of ethinyl estradiol for Venous Thrombosis and 2 related conditions. Completed, enrolled 598,682 participants.
Detailed Summary
Lybrel® is an oral contraceptive that delivers low doses of levonorgestrel and ethinyl estradiol (90 μg/20 μg). Lybrel is taken on a continuous basis without a placebo or pill-free interval to inhibit menstrual cycle bleeding by delivering a steady level of the 2 hormones for as long as the drug is used. Lybrel was marketed in the US in July of 2007. The objective of this database case-control study is to estimate the risk of idiopathic VTE (deep vein thrombosis and pulmonary embolism) in current users of Lybrel (ethinyl estradiol 20ug/levonorgestrel 90ug) compared to current users of other oral contraceptives containing 20μg of ethinyl estradiol.
Study Details
Timeline
Interventions
This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
This is a non-interventional observational database study, thus no interventions are offered to patients in the study.